Investigational drug · Phase 2
CNP-103
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Type 1 Diabetes Mellitus, T1D, T1DM.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "CNP-103"
First trial start
2025
May 12, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CNP-103", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 1 Diabetes Mellitus
- T1D
- T1DM
- T1DM - Type 1 Diabetes Mellitus
- Type 1 Diabetes in Adolescence
- Type 1 Diabetes in Children
- Type 1 Diabetes (Juvenile Onset)
- Type 1 Diabetes
- Type 1 Diabetes Patients
- Type 1 Diabetes Mellitis
Approved drugs for the same conditions: Type 1 diabetes · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "CNP-103" as an intervention, largest first.
COUR Pharmaceutical Development Company, Inc.Industry
NCT06783309 · 72 participants (planned) · Start May 12, 2025 · Primary completion Aug 2027
Drug: CNP-103; Placebo · For: Type 1 Diabetes Mellitus; T1D; T1DM and 7 more
Sites: Tucson, Arizona; Newport Beach, California; San Diego, California · 45 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Type 1 Diabetes Mellitus
- FrexalimabSAR441344Phase 39 trials
Sanofi · Multiple Sclerosis, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
- rilparencelRenal Autologous Cell Therapy, REACTPhase 32 trials
Prokidney · Type 2 Diabetes Mellitus, Chronic Kidney Diseases, Type 1 Diabetes Mellitus
- brivekimigSAR442970Phase 25 trials
Sanofi · Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Type 1 Diabetes Mellitus
- BMF-219Phase 22 trials
Biomea Fusion Inc. · Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus
- AcmopatideCT-868, RO7795074Phase 21 trial
Carmot Therapeutics, Inc. · Overweight, Obese, Type 1 Diabetes Mellitus
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.